Despite progress understanding the costs and benefits of diversity in corporate boardrooms we continue to have many unanswered questions. As questions begin to be partially answered, more questions arise. Here I explore those layers of the boardroom diversity onion.
No takes yet. Share an insight, caveat, or question.
Amy J. Hillman (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: